Viking Therapeutics, Inc.
VKTXW
VKTXW was delisted on the 8th of April, 2021.
0 hedge funds and large institutions have $0 invested in Viking Therapeutics, Inc. in 2021 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $497K → $0 (-$497K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$449K |
| 2 |
Morgan Stanley
New York
|
-$46K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PWAM
1
Park West Asset Management
San Francisco,
California
| – | -$449K | -95,600 | Closed |
|
|
2
Morgan Stanley
New York
| – | -$46K | -9,700 | Closed |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$2K | -388 | Closed |
|
VKTXW Hedge Fund Activity: Q2 2021 in Review
0 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics, Inc. (VKTXW) for Q2 2021, worth a combined $0 — down 100% from $497K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of VKTXW and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Park West Asset Management, exiting entirely with an estimated $449K sold.
- 0 institutional investors held Viking Therapeutics, Inc. (VKTXW) as of Q2 2021, down from 3 in Q1 2021.
- Funds reported $0 of Viking Therapeutics, Inc. stock for Q2 2021, down 100% quarter-over-quarter.
- 0 funds opened new Viking Therapeutics, Inc. positions in Q2 2021 and 3 closed out, a net change of -3 holders.
- The largest Viking Therapeutics, Inc. seller in Q2 2021 was Park West Asset Management, an estimated $449K sold.
Based on aggregated 13F filings for Q2 2021.